|
Title
|
Published
|
Price
|
|
Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
By: Datamonitor
Introduction
Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the
|
more...
|
11/12/2009
|
$7,600.00
|
|
Generic Pharmaceuticals Industry Report
By: Plimsoll Publishing Ltd.
The Global Generic Pharmaceuticals Industry Report Plimsoll Publishing Ltd. Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt? This report is an in-depth
|
more...
|
11/1/2009
|
$1,500.00
|
|
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
By: Aruvian's R'search
Pharmaceutical is one of the most intense “Knowledge Driven” industries, which is continually in a state of dynamic transition.Diversities in life forms and diseases pose stiff challenge to the design of specific and targeted solutions.
|
more...
Search inside this report
|
11/1/2009
|
$175.00
|
|
Asia Pacific Pharma Sector Analysis
By: RNCOS
The world continues to witness significant shift in the global pharmaceutical market landscape, with Asia-Pacific emerging as the fastest growing pharmaceutical market over the recent past. With low costs and favorable regulatory environment, the region
|
more...
|
11/1/2009
|
$1,200.00
|
|
Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion
By: Datamonitor
Introduction In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in the US where incursion is
|
more...
|
10/28/2009
|
$15,200.00
|
|
Antipsychotics Market Forecast
By: Datamonitor
Introduction In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in the US where incursion is
|
more...
|
10/28/2009
|
$15,200.00
|
|
Generics: Global Industry Guide
By: Datamonitor
Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the Generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive
|
more...
Search inside this report
|
10/14/2009
|
$1,495.00
|
|
Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential
By: Datamonitor
Introduction In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therapeutic drug classes in the Pharmaceutical sector. However, generic incursion of second generation anticonvulsants will continue to increase
|
more...
|
10/8/2009
|
$15,200.00
|
|
Partnering in the Global Generics Industry 2008: A Guide to Companies
By: Espicom Healthcare Intelligence
Partnering is increasingly the choice for securing market share and business growth...
... Teva’s recent acquisition of Barr Pharmaceuticals may be the latest headline grabbing deal, but industry and commerce alike must have a complete
|
more...
Search inside this report
|
10/6/2009
|
$1,130.00
|
|
China Hospital Drug Utilization Volume Executive Summary 2nd Edition 2009
By: Draco Healthcare Consulting LLC
The total Chinese pharmaceutical market had reached RMB 828.36 billion (US$ 120.84 billion, at an exchange rate of US $1 = RMB 6.83) with an annual growth rate (AGR) of 26.50% in 2008. The growth
|
more...
|
10/1/2009
|
$4,400.00
|
|
Cardiovascular Outlook: Pharmaceutical, Medical Device, New Technologies - Past, Present, and Future
By: Canon Communications, LLC
Cardiovascular disease is the leading cause of death in the United States, affecting an estimated 80.7 million American adults, with estimated treatment costs of more than $313.8 billion annually. This report contains qualitative analysis of
|
more...
|
10/1/2009
|
$535.00
|
|
The Outlook for Pharmaceuticals in Western Europe
By: Espicom Healthcare Intelligence
The countries of Western Europe represent a total market of over 365 million people and a combined GDP of US$14.4 trillion in 2007.
The 11 main Western European markets for pharmaceuticals are wealthy and
|
more...
|
9/30/2009
|
$3,790.00
|
|
The Outlook for Pharmaceuticals in South East Asia
By: Espicom Healthcare Intelligence
The eight Asian countries covered in this service represented a total market of 588 million people and a combined GDP of US$2.8 trillion in 2008
Business opportunities in Asian pharmaceutical markets are very different
|
more...
|
9/30/2009
|
$3,790.00
|
|
The Outlook for Pharmaceuticals in Northern Europe
By: Espicom Healthcare Intelligence
The Outlook for Pharmaceutical Markets in Northern Europe is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political,
|
more...
|
9/30/2009
|
$3,790.00
|
|
The Outlook for Pharmaceuticals in Latin America
By: Espicom Healthcare Intelligence
The pharmaceutical markets in Latin America are worth US$50 billion - and growing fast!
The eight Latin American markets covered by Espicom Business Intelligence represent a market of 474 million people with a GDP
|
more...
|
9/30/2009
|
$3,790.00
|
|
The Pharmaceutical Market: Peru
By: Espicom Healthcare Intelligence
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section
|
more...
Search inside this report
|
9/30/2009
|
$1,130.00
|
|
The Pharmaceutical Market: India
By: Espicom Healthcare Intelligence
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section
|
more...
|
9/30/2009
|
$1,130.00
|
|
The Pharmaceutical Market: Chile
By: Espicom Healthcare Intelligence
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section
|
more...
|
9/30/2009
|
$1,130.00
|
|
E7: The Outlook for Pharmaceuticals to 2012
By: Espicom Healthcare Intelligence
E7: The Outlook for Pharmaceuticals to 2012 is a new collection of management reports from Espicom Business Intelligence. Each report provides an individual and highly-detailed analysis of each market, looking at the key regulatory,
|
more...
|
9/30/2009
|
$3,790.00
|
|
Pharmaceutical Pricing and Reimbursement in India
By: Decision Resources
Introduction
Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies
are looking to substantially increase their sales in India and other emerging markets. The Indian market
is growing by more
|
more...
|
9/25/2009
|
$2,250.00
|
|
The Global Generic Pharmaceuticals Industry Report
By: Plimsoll Publishing Ltd.
The Global Generic Pharmaceuticals Industry Report Plimsoll Publishing Ltd. Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt? This report is an in-depth
|
more...
|
9/24/2009
|
$1,500.00
|
|
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
By: Decision Resources
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as
creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses
|
more...
|
9/18/2009
|
$2,250.00
|
|
Generics in the United States
By: Datamonitor
Datamonitor's Generics in the United States industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, plus textual and graphical analysis
|
more...
Search inside this report
|
9/2/2009
|
$250.00
|
|
Generics in the United Kingdom
By: Datamonitor
Datamonitor's Generics in the United Kingdom industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, plus textual and graphical analysis
|
more...
Search inside this report
|
9/2/2009
|
$250.00
|
|
Generics in Spain
By: Datamonitor
Datamonitor's Generics in Spain industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, plus textual and graphical analysis of the
|
more...
Search inside this report
|
9/2/2009
|
$250.00
|
|
Title
|
Published
|
Price
|
(0 items)
